Anixa Biosciences (ANIX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

Anixa Biosciences Revenue Highlights

Latest Revenue (Y)

$210.00K

Main Segment (Y)

Patent Licensing

Main Geography (Y)

Patent Licensing

Anixa Biosciences Revenue by Period

Anixa Biosciences Revenue by Year

Date	Revenue	Change
2023-10-31	$210.00K	-99.99%
2022-10-31	$2.47B	481656.10%
2021-10-31	$512.50K	100.00%
2020-10-31	-	-100.00%
2019-10-31	$250.00K	-77.53%
2018-10-31	$1.11M	206.90%
2017-10-31	$362.50K	20.83%
2016-10-31	$300.00K	-96.76%
2015-10-31	$9.26M	152.36%
2014-10-31	$3.67M	843.12%
2013-10-31	$388.85K	-58.94%
2012-10-31	$947.09K	-5.59%
2011-10-31	$1.00M	37.30%
2010-10-31	$730.67K	-30.79%
2009-10-31	$1.06M	-48.83%
2008-10-31	$2.06M	323.77%
2007-10-31	$486.85K	-4.29%
2006-10-31	$508.65K	15.66%
2005-10-31	$439.79K	-11.06%
2004-10-31	$494.46K	102.46%
2003-10-31	$244.22K	-95.29%
2002-10-31	$5.19M	206.77%
2001-10-31	$1.69M	14.86%
2000-10-31	$1.47M	1372.00%
1999-10-31	$100.00K	-50.00%
1998-10-31	$200.00K	100.00%
1997-10-31	$100.00K	-
1996-10-31	$100.00K	-
1995-10-31	$100.00K	-
1994-10-31	$100.00K	-
1993-10-31	$100.00K	-

Anixa Biosciences generated $210.00K in revenue during NA 2023, up -99.99% compared to the previous quarter, and up 18.88% compared to the same period a year ago.

Anixa Biosciences Revenue by Quarter

Date	Revenue	Change
2024-07-31	-	100.00%
2024-04-30	-	100.00%
2024-01-31	-	-100.00%
2023-10-31	$156.00K	100.00%
2023-07-31	-	-100.00%
2023-04-30	$210.00K	100.00%
2023-01-31	-	-100.00%
2022-10-31	$2.47B	100.00%
2022-07-31	-	100.00%
2022-04-30	-	100.00%
2022-01-31	-	-100.00%
2021-10-31	$3.61M	100.00%
2021-07-31	-	100.00%
2021-04-30	-	-100.00%
2021-01-31	$512.50K	-512.11%
2020-10-31	$-124.36K	100.00%
2020-07-31	-	100.00%
2020-04-30	-	100.00%
2020-01-31	-	-100.00%
2019-10-31	$-259.48K	100.00%
2019-07-31	-	-100.00%
2019-04-30	$250.00K	100.00%
2019-01-31	-	-100.00%
2018-10-31	$-1.42M	-491.84%
2018-07-31	$362.50K	-51.67%
2018-04-30	$750.00K	100.00%
2018-01-31	-	-100.00%
2017-10-31	$-74.91K	-120.66%
2017-07-31	$362.50K	100.00%
2017-04-30	-	100.00%
2017-01-31	-	-100.00%
2016-10-31	$200.00K	100.00%
2016-07-31	$100.00K	100.00%
2016-04-30	-	100.00%
2016-01-31	-	100.00%
2015-10-31	-	-100.00%
2015-07-31	$95.00K	280.00%
2015-04-30	$25.00K	-99.73%
2015-01-31	$9.13M	564.36%
2014-10-31	$1.38M	15.81%
2014-07-31	$1.19M	7.45%
2014-04-30	$1.10M	100.00%
2014-01-31	-	-100.00%
2013-10-31	$386.72K	100.00%
2013-07-31	-	100.00%
2013-04-30	-	-100.00%
2013-01-31	$2.13K	508.57%
2012-10-31	$350.00	-99.86%
2012-07-31	$249.47K	0.56%
2012-04-30	$248.07K	-44.77%
2012-01-31	$449.19K	0.05%
2011-10-31	$448.96K	-0.31%
2011-07-31	$450.36K	418.16%
2011-04-30	$86.92K	412.53%
2011-01-31	$16.96K	-94.55%
2010-10-31	$311.25K	436.36%
2010-07-31	$58.03K	-82.01%
2010-04-30	$322.52K	729.75%
2010-01-31	$38.87K	-67.38%
2009-10-31	$119.16K	-60.25%
2009-07-31	$299.76K	14.09%
2009-04-30	$262.75K	-29.77%
2009-01-31	$374.12K	-61.17%
2008-10-31	$963.41K	9.21%
2008-07-31	$882.13K	433.48%
2008-04-30	$165.35K	216.62%
2008-01-31	$52.23K	-

Anixa Biosciences generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Anixa Biosciences Revenue Breakdown

Anixa Biosciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Oct 19
Patent Licensing	$250.00K

Anixa Biosciences's latest annual revenue breakdown by segment (product or service), as of Oct 19: Patent Licensing (100.00%).

Anixa Biosciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Oct 19
Patent Licensing	$250.00K

Anixa Biosciences's latest annual revenue breakdown by geography, as of Oct 19: Patent Licensing (100.00%).

Anixa Biosciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ACLX	Arcellx	$110.32M	$26.03M
ADAG	Adagene	$18.11M	$833.34K
IMNM	Immunome	$14.02M	$2.91M
MOLN	Molecular Partners	$7.04M	$2.74M
CUE	Cue Biopharma	$5.49M	$3.34M
TFFP	TFF Pharmaceuticals	$733.87K	$650.22K
ANIX	Anixa Biosciences	$210.00K	-
ANEB	Anebulo Pharmaceuticals	-	-
RZLT	Rezolute	-	-
ANTX	AN2 Therapeutics	-	-
AVTE	Aerovate Therapeutics	-	-
INAB	IN8bio	-	-
ACRV	Acrivon Therapeutics	-	-
PMVP	PMV Pharmaceuticals	-	-
MLYS	Mineralys Therapeutics	-	-
PYPD	PolyPid	-	-
ANVS	Annovis Bio	-	-
INMB	INmune Bio	$-155.00K	-

ANIX Revenue FAQ

What is Anixa Biosciences’s yearly revenue?

Anixa Biosciences's yearly revenue for 2023 was $210K, representing a decrease of -99.99% compared to 2022. The company's yearly revenue for 2022 was $2.47B, representing an increase of 481656.10% compared to 2021. ANIX's yearly revenue for 2021 was $512.5K, representing an increase of 100.00% compared to 2020.

What is Anixa Biosciences’s quarterly revenue?

Anixa Biosciences's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). ANIX's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Anixa Biosciences’s revenue growth rate?

Anixa Biosciences's revenue growth rate for the last 3 years (2021-2023) was -59.02%, and for the last 5 years (2019-2023) was -16.00%.

What are Anixa Biosciences’s revenue streams?

Anixa Biosciences's revenue streams in t 19 are Patent Licensing

What is Anixa Biosciences’s main source of revenue?

For the fiscal year ending Oct 19, the largest source of revenue of Anixa Biosciences was Patent Licensing. This segment made a revenue of $250K, representing 100.00% of the company's total revenue.